Patient Centric Monitoring is ICON’s methodology for the design and execution of an adaptive risk based monitoring strategy using ICONIK analysis. Read about our approach and how ICON is realising efficiencies and quality improvements for its customers today.
Hear perspectives from ICON’s Uma Arumugam, MD in Applied Clinical Trials on utilizing historical data and employing clinically meaningful outcomes in a clinical trial design.
An ICON White Paper: The determination of the maximum tolerated dose (MTD) level is a critical step in oncology drugevelopment. High doses are needed to improve the efficacy of the drug, but can result in an increased number and severity of undesired drug limiting toxic (DLT) reactions.
ICT (International Clinical Trials talks to ICON Clinical Services' new President, Nuala Murphy, about her business thinking and how expertise and good data lie behind the best solution
ICON’s Dr. Chad Ray published this article in Bioanalysis Magazine on overcoming the challenges biomarkers present in demonstrating accuracy due to analytes that are endogenous, heterogeneous and often structurally different from the calibrator.
By Dr. Greg Goldmacher, Sr Dir Med & Scientific Affrs, Medical Affairs, ICON
ICON’s Dr Cyril Clarke and Dr Pinar Akpinar published this article in European Biopharmaceutical Review exploring proof- of-concept and proof-of-value; and whether they’re inexorably interlinked or destined to meet too late.
By. Dr's. Jamal Gasmi, James Conklin and Gregory Goldmacher. The pharmaceutical industry’s R&D productivity is hampered by the reality behind one disheartening statistic: over 40 percent of all therapeutic agents deemed successful in Phase II programs subsequently fail in Phase III studies. Given the cost of Phase III trials, companies pay a staggering price for their inability to identify unsuccessful candidates prior to late-stage development.
Maximizing Development Efficiency, Productivity and Investment Decision-Making